Table 2.
Comparison of clinical and pathological features of breast cancer among the different body mass index groups.
| Characteristics | UWn (%) | NWn (%) | OWn (%) | OBn (%) | Subtotaln (%) |
|---|---|---|---|---|---|
| 66 | 642 | 277 | 55 | 1040 | |
| Tumor size | |||||
| ≤2 cm | 33 (50.0) | 236 (36.8) | 111 (40.1) | 11 (20.0) | 391 (37.6) |
| 2–5 cm | 28 (42.4) | 359 (55.9) | 128 (46.2) | 38 (69.1) | 553 (53.2) |
| >5 cm | 5 (7.6) | 47 (7.3) | 38 (13.7) | 6 (10.9) | 96 (9.2) |
| P value | <0.01** | ||||
| Axillary lymph nodes | |||||
| Negative | 38 (57.6) | 329 (51.2) | 140 (50.5) | 24 (43.6) | 531 (51.1) |
| Positive | 28 (42.4) | 313 (48.8) | 137 (49.5) | 31 (56.4) | 509 (48.9) |
| P value | 0.499* | ||||
| TNM stage | |||||
| Early (I + II) | 31 (47.0) | 307 (47.8) | 105 (37.9) | 22 (40.0) | 465 (44.7) |
| Advanced (III) | 35 (53.0) | 335 (52.2) | 172 (62.1) | 33 (60.0) | 575 (55.3) |
| P value | 0.04** | ||||
| Pathological diagnosis | |||||
| Ductal carcinoma | 53 (80.3) | 529 (82.4) | 221 (79.8) | 46 (83.6) | 849 (81.6) |
| Lobular carcinoma | 7 (10.6) | 54 (8.4) | 27 (9.7) | 5 (9.1) | 93 (8.9) |
| Others | 6 (9.1) | 59 (9.2) | 29 (10.5) | 4 (7.3) | 98 (9.4) |
| P value | 0.955*** | ||||
| Tumor site | |||||
| Left | 32 (48.5) | 339 (52.8) | 136 (49.1) | 28 (50.9) | 535 (51.4) |
| Right | 34 (51.5) | 303 (47.2) | 141 (50.9) | 27 (49.1) | 505 (48.6) |
| P value | 0.724* | ||||
| Molecular subtype | |||||
| Luminal A | 34 (51.5) | 322 (50.2) | 143 (51.6) | 30 (54.5) | 529 (50.9) |
| Luminal B | 9 (13.6) | 118 (18.4) | 42 (15.2) | 8 (14.5) | 177 (17.0) |
| Her2+ | 7 (10.6) | 74 (11.5) | 26 (9.4) | 4 (7.3) | 111 (10.7) |
| TN | 16 (24.2) | 128 (19.9) | 66 (23.8) | 13 (23.6) | 223 (21.4) |
| P value | 0.799* |
UW, underweight; NW, normal weight; OW, overweight; OB, obese; TNM, tumor-node-metastasis; Her2, human epidermal growth factor receptor 2; TN, triple-negative. *Chi-square test; **rank-sum test; ***Fisher’s exact test.